Clinical Trial Update: Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of autologous T cells engineered to express T-cell receptors (TCRs) in patients with solid tumors was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Endometrial Cancer
• Lung Adenocarcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Squamous Cell Lung Cancer

Drugs mentioned

• Autologous T-cell receptor (TCR) therapy (TCR-engineered autologous T cells)

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Gynecologic Cancer, Colorectal Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-11-10